Skip to main navigation Skip to search Skip to main content

Factor IXa inhibitors as novel anticoagulants

  • Duke University

Research output: Contribution to journal › Review article › peer-review

87 Scopus citations

Abstract

Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.

Original languageEnglish
Pages (from-to)722-727
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume27
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Keywords

  • Anticoagulants
  • Coagulation
  • Factor IX (fIX), monoclonal antibodies (mAb), RNA aptamers

Fingerprint

Dive into the research topics of 'Factor IXa inhibitors as novel anticoagulants'. Together they form a unique fingerprint.

Cite this